Sankalp康复信托基金在印度对Gilead Science的lenacapavir专利申请提出了挑战, Sankalp Rehabilitation Trust challenges Gilead Sciences' lenacapavir patent application in India, arguing it's based on a known compound and blocking generic alternatives.

印度专利局将审理Sankalp康复基金会对吉利德科学公司对莱纳卡巴维尔 (lenacapavir) 的专利申请的挑战, India's patent office will hear a challenge from Sankalp Rehabilitation Trust against Gilead Sciences' patent applications for lenacapavir, a costly HIV prevention drug priced over $40,000 annually. 积极分子认为,该药物是以已知化合物为基础的,给予专利可以阻止负担得起的非专利替代品,限制数百万人获得。 Activists argue the drug is based on a known compound, and granting the patent could block affordable generic alternatives, limiting access for millions. 这一反对派是促进竞争和确保获得艾滋病毒基本治疗的更广泛全球运动的一部分。 This opposition is part of a broader global movement to promote competition and ensure access to essential HIV treatments.